NCT02170077View on ClinicalTrials.gov

A Placebo-controlled Study to Investigate Safety and Efficacy of BIA 2-093

PHASE2CompletedINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

April 30, 2002

Primary Completion Date

November 30, 2002

Study Completion Date

November 30, 2002

Conditions
Epilepsy
Interventions
DRUG

BIA 2-093

BIA 2-093 (tablets) administered at increasing daily doses of 400 mg, 800 mg and 1200 mg once-daily or twice-daily, oral route

DRUG

Placebo

Placebo tablets administered orally

Trial Locations (1)

4045-457

BIAL - Portela & Cª, S.A., S. Mamede Do Coronado

All Listed Sponsors
lead

Bial - Portela C S.A.

INDUSTRY

NCT02170077 - A Placebo-controlled Study to Investigate Safety and Efficacy of BIA 2-093 | Biotech Hunter | Biotech Hunter